WD is diagnosed on the basis of several symptoms and biomarkers that encompass hepatic, neurological, or psychiatric clinical signs, low levels of ceruloplasmin, increased levels of non-ceruloplasmin bound copper (also known as ‘free’ copper) in serum and urine, and the identification of ATP7B gene mutations [1,2]. This evidence concerns the gene ATP7B and Wilson disease.